Skip to main content
Erschienen in: Supportive Care in Cancer 2/2017

12.10.2016 | Original Article

Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor

verfasst von: Derek Weycker, Xiaoyan Li, Spiros Tzivelekis, Mark Atwood, Jacob Garcia, Yanli Li, Maureen Reiner, Gary H. Lyman

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Evidence suggests that many cancer chemotherapy patients who are candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it inconsistent with guidelines, and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). Little is known about the number and consequences of FNH by use/patterns of CSF prophylaxis in US clinical practice.

Methods

A retrospective cohort design and private healthcare claims data were employed. Study population comprised adults who received a chemotherapy course with a high-risk regimen, or an intermediate-risk regimen (if ≥1 FN risk factor present), for non-metastatic breast cancer or non-Hodgkin’s lymphoma (NHL); each chemotherapy cycle within the course and each FNH episode within the cycles were identified. Consequences included mortality, inpatient days, and costs (US$2013) during FNH. Use (yes/no) and patterns (agent, administration day/duration) of CSF prophylaxis were evaluated within cycles in which FNH episodes occurred.

Results

Among all FNH episodes (n=6,355; 109 episodes per 1,000 patients), 41.3% (95% CI: 40.1-42.5) occurred among patients who did not receive CSF prophylaxis in that cycle, and 8.8% (8.1-9.5) occurred among those who received CSF prophylaxis on the same day as chemotherapy. Among FNH episodes occurring in patients who received daily CSF agents (2% of CSF use), 56.1% (44.1-68.0) received prophylaxis <7 days during the cycle. Results for FNH consequences were comparable.

Conclusions

In this retrospective evaluation, one-half of FNH episodes, outcomes, and costs among cancer chemotherapy patients who were candidates for CSF prophylaxis occurred in those who either did not receive it or received it inconsistent with guidelines.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G (2008) Cost of neutropenic complications of chemotherapy. Ann Oncol 19(3):454–460CrossRefPubMed Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G (2008) Cost of neutropenic complications of chemotherapy. Ann Oncol 19(3):454–460CrossRefPubMed
2.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266CrossRefPubMed Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266CrossRefPubMed
3.
Zurück zum Zitat Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205CrossRefPubMed Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205CrossRefPubMed
4.
Zurück zum Zitat Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924CrossRefPubMed Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924CrossRefPubMed
5.
Zurück zum Zitat Network NCC: (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Myeloid Growth Factors, Version 2. Network NCC: (2015) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Myeloid Growth Factors, Version 2.
6.
Zurück zum Zitat Neulasta (Pegfilgrastim) (2015) Prescribing Information. Amgen Inc., Neulasta (Pegfilgrastim) (2015) Prescribing Information. Amgen Inc.,
7.
Zurück zum Zitat Neupogen (Filgrastim) (2015) Prescribing Information. Amgen Inc. Neupogen (Filgrastim) (2015) Prescribing Information. Amgen Inc.
8.
Zurück zum Zitat Granix (tbo-filgrastim) (2015) Prescribing Information. Teva Pharmaceuticals Granix (tbo-filgrastim) (2015) Prescribing Information. Teva Pharmaceuticals
9.
Zurück zum Zitat Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184CrossRefPubMed Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178–1184CrossRefPubMed
10.
Zurück zum Zitat Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35CrossRefPubMed Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29–35CrossRefPubMed
11.
Zurück zum Zitat Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909CrossRefPubMed Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903–909CrossRefPubMed
12.
Zurück zum Zitat Trillet-Lenoir V, Green J, Manegold C, Von Pavel J, Gatzemeier U, Lebeau B et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324CrossRefPubMed Trillet-Lenoir V, Green J, Manegold C, Von Pavel J, Gatzemeier U, Lebeau B et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324CrossRefPubMed
13.
Zurück zum Zitat Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170CrossRefPubMed Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170CrossRefPubMed
14.
Zurück zum Zitat Leukine (Sargramostim) (2009) Package Insert. Pittsburgh, PA, Bayer Inc, Leukine (Sargramostim) (2009) Package Insert. Pittsburgh, PA, Bayer Inc,
15.
Zurück zum Zitat Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G (2012) Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in cancer chemotherapy patients. Am J Clin Oncol 35(3):267–274. doi:10.1097/COC.0b013e31820dc075 CrossRefPubMed Weycker D, Malin J, Barron R, Edelsberg J, Kartashov A, Oster G (2012) Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in cancer chemotherapy patients. Am J Clin Oncol 35(3):267–274. doi:10.​1097/​COC.​0b013e31820dc075​ CrossRefPubMed
16.
Zurück zum Zitat Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS (2009) Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. Cancer 115:4839–4848CrossRefPubMed Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS (2009) Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-Induced neutropenia. Cancer 115:4839–4848CrossRefPubMed
17.
Zurück zum Zitat Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2015a) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: Does timing of administration matter? Supportive Care in Cancer. doi:10.1007/s00520-015-3036-7 Weycker D, Li X, Figueredo J, Barron R, Tzivelekis S, Hagiwara M (2015a) Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: Does timing of administration matter? Supportive Care in Cancer. doi:10.​1007/​s00520-015-3036-7
18.
Zurück zum Zitat Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A et al (2015b) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Supportive Care in Cancer. doi:10.1007/s00520-015-3039-4 Weycker D, Li X, Barron R, Li Y, Reiner M, Kartashov A et al (2015b) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice. Supportive Care in Cancer. doi:10.​1007/​s00520-015-3039-4
19.
Zurück zum Zitat Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM (2014) Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer 22:2167–2175. doi:10.1007/s00520-014-2184-5 CrossRefPubMed Langeberg WJ, Siozon CC, Page JH, Morrow PK, Chia VM (2014) Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer 22:2167–2175. doi:10.​1007/​s00520-014-2184-5 CrossRefPubMed
20.
Zurück zum Zitat Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290–4296CrossRefPubMed Aarts MJ, Peters FP, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ et al (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290–4296CrossRefPubMed
21.
Zurück zum Zitat Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79–86CrossRefPubMed Tan H, Tomic K, Hurley D, Daniel G, Barron R, Malin J (2011) Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 27:79–86CrossRefPubMed
22.
Zurück zum Zitat Potosky A, Malin J, Kim B, Chrischilles E, Makgoeng S, Howlader N, Weeks J (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103(12):979–982CrossRefPubMedPubMedCentral Potosky A, Malin J, Kim B, Chrischilles E, Makgoeng S, Howlader N, Weeks J (2011) Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103(12):979–982CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Weycker D, Malin J, Kim J, Kim J, Barron R, Edelsberg J et al (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081CrossRefPubMed Weycker D, Malin J, Kim J, Kim J, Barron R, Edelsberg J et al (2009) Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 31:1069–1081CrossRefPubMed
24.
Zurück zum Zitat Schuman SI, Lambrou N, Robson K, Glück S, Myriounis N, Pearson JM et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228PubMed Schuman SI, Lambrou N, Robson K, Glück S, Myriounis N, Pearson JM et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228PubMed
25.
Zurück zum Zitat Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13(4):337–348PubMed Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J (2007) Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm 13(4):337–348PubMed
26.
Zurück zum Zitat Naeim A, Friedman L, Pasta DJ (2007) Prophylaxis of chemotherapy-induced neutropenia: Patterns of care in U.S. community oncology practices. Journal of Clinical Oncology 25 (Abstract #9123) Naeim A, Friedman L, Pasta DJ (2007) Prophylaxis of chemotherapy-induced neutropenia: Patterns of care in U.S. community oncology practices. Journal of Clinical Oncology 25 (Abstract #9123)
27.
Zurück zum Zitat Lokich JJ (2006) Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 29:361–363CrossRefPubMed Lokich JJ (2006) Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol 29:361–363CrossRefPubMed
28.
Zurück zum Zitat Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407CrossRefPubMed Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402–407CrossRefPubMed
29.
Zurück zum Zitat Hoffman P (2005) Administration of pegfilgrastim on the same day or next day of chemotherapy. ASCO American Society of Clinical Oncology Annual Meeting (Abstract #8137) Hoffman P (2005) Administration of pegfilgrastim on the same day or next day of chemotherapy. ASCO American Society of Clinical Oncology Annual Meeting (Abstract #8137)
30.
Zurück zum Zitat Hershman D, Hurley D, Wong M, Morrison VA, Malin JL (2009) Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 12:203–210CrossRefPubMed Hershman D, Hurley D, Wong M, Morrison VA, Malin JL (2009) Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 12:203–210CrossRefPubMed
31.
Zurück zum Zitat Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A et al (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 16:160–168CrossRefPubMed Henk HJ, Becker L, Tan H, Yu J, Kavati A, Naeim A et al (2013) Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses. J Med Econ 16:160–168CrossRefPubMed
32.
Zurück zum Zitat Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin's lymphoma: Results of four multicenter, double-blind, randomized phase ii studies. J Oncol Pract 6:133–140CrossRefPubMedPubMedCentral Burris HA, Belani CP, Kaufman PA, Gordon AN, Schwartzberg LS, Paroly WS et al (2010) Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-hodgkin's lymphoma: Results of four multicenter, double-blind, randomized phase ii studies. J Oncol Pract 6:133–140CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Cheng C, Gallagher EM, Yeh JY, Earl MA (2014) Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anticancer Drugs 25:964–969CrossRefPubMed Cheng C, Gallagher EM, Yeh JY, Earl MA (2014) Rates of febrile neutropenia with pegfilgrastim on same day versus next day of CHOP with or without rituximab. Anticancer Drugs 25:964–969CrossRefPubMed
34.
Zurück zum Zitat Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 77:107–112CrossRefPubMed Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E et al (2009) Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. Oncology 77:107–112CrossRefPubMed
35.
Zurück zum Zitat Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601–604CrossRefPubMed Whitworth JM, Matthews KS, Shipman KA, Numnum TM, Kendrick JE, Kilgore LC et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112:601–604CrossRefPubMed
36.
Zurück zum Zitat Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9:15–21PubMed Scott SD, Chrischilles EA, Link BK, Delgado DJ, Fridman M, Stolshek BS (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9:15–21PubMed
38.
Zurück zum Zitat Schnipper L, Smith T, Raghavan D, Blayney D, Ganz P, Mulvey T, Wollins D (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30(14):1715–1724CrossRefPubMed Schnipper L, Smith T, Raghavan D, Blayney D, Ganz P, Mulvey T, Wollins D (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30(14):1715–1724CrossRefPubMed
39.
Zurück zum Zitat Waters G, Corrigan P, Gatesman M, Smith T (2013) Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 9(4):203–206CrossRefPubMed Waters G, Corrigan P, Gatesman M, Smith T (2013) Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 9(4):203–206CrossRefPubMed
40.
Zurück zum Zitat Kuderer N, Lyman G (2011) Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst 103(12):910–913CrossRefPubMedPubMedCentral Kuderer N, Lyman G (2011) Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst 103(12):910–913CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J (2013) Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 13 Weycker D, Sofrygin O, Seefeld K, Deeter RG, Legg J, Edelsberg J (2013) Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases. BMC Health Serv Res 13
Metadaten
Titel
Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor
verfasst von
Derek Weycker
Xiaoyan Li
Spiros Tzivelekis
Mark Atwood
Jacob Garcia
Yanli Li
Maureen Reiner
Gary H. Lyman
Publikationsdatum
12.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3421-x

Weitere Artikel der Ausgabe 2/2017

Supportive Care in Cancer 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.